Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic–uremic syndrome in Japan: interim analysis of post-marketing surveillance

Shuichi Ito1 · Yoshihiko Hidaka2 · Norimitsu Inoue3 · Shinya Kaname4 · Hideki Kato5 · Masanori Matsumoto6 · Yoshitaka Miyakawa7 · Masashi Mizuno8 · Hirokazu Okada9 · Akihiko Shiono10 · Takahisa Matsuda10 · Shoichi Maruyama8 · Yoshihiro Fujimura11 · Masaomi Nangaku5 · Shoji Kagami12

Received: 5 April 2018 / Accepted: 18 June 2018 / Published online: 23 July 2018
© The Author(s) 2018

Abstract

Background In 2013, eculizumab was approved for treatment of the atypical hemolytic–uremic syndrome (aHUS) in Japan, which was defined as a thrombotic microangiopathy (TMA) excluding Shiga toxin-producing Escherichia coli-HUS and thrombotic thrombocytopenic purpura. Simultaneously, post-marketing surveillance was started to assess its safety and effectiveness. In 2016, Japanese clinical guide redefined terms to limit the use of “aHUS” to complement-mediated HUS only. Accordingly, TMA with other causes was defined as secondary TMA. Here we report the interim analysis of post-marketing surveillance of pediatric patients with aHUS and secondary TMA.

Methods Pediatric patients treated with eculizumab from approval to 15 March 2017 were included in this observational real-world study. Clinical endpoints of effectiveness were TMA event–free status, complete TMA response, platelet count normalization, and improvement of estimated glomerular filtration rate (eGFR). Adverse reactions to eculizumab were also analyzed.

Results In 27 pediatric patients with aHUS, median age at diagnosis was 4 years. Complement genes’ variants were detected in 14 of 21 patients (66.7%). Median time from diagnosis to eculizumab initiation was 2.0 days. TMA event–free status, complete TMA response, platelet count normalization, and improvement in eGFR were achieved in 85.2, 36.4, 78.3, and 75.0% of patients, respectively. Three patients with aHUS died. Twenty-four and 10 adverse reactions were reported in 31 aHUS patients and 17 secondary TMA patients, respectively; however, no eculizumab-related death or meningococcal infection was reported.

Conclusions This interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.

Keywords Atypical hemolytic–uremic syndrome · Post-marketing surveillance · Complement protein C5 inhibitor · Eculizumab

Introduction

Atypical hemolytic–uremic syndrome (aHUS), a thrombotic microangiopathy (TMA), is a rare disease characterized by the triad of microangiopathic hemolytic anemia (MAHA), thrombocytopenia, and acute kidney injury (AKI) [1, 2]. The prognosis of aHUS was very poor; 29–48% of children with aHUS progressed to end-stage renal disease or death within 1 year when the mainstay of treatment was plasma therapy [3, 4].

Eculizumab (Soliris®, Alexion Pharmaceuticals) is a recombinant humanized monoclonal antibody against
complement protein 5 (C5). Based on results from clinical studies [5, 6], it was approved for treatment of aHUS in Japan in September 2013 [7]. Eculizumab binds C5 and blocks cleavage of C5 to C5a and C5b, thus inhibiting formation of the terminal complement complex. Pivotal clinical studies showed that eculizumab significantly inhibited complement-mediated TMA and improved renal function in a time-dependent manner [6]. Since aHUS is rare, and data on its safety and effectiveness are limited, especially in Japan, the Ministry of Health, Labour and Welfare of Japan requested Alexion Pharma GK to monitor all aHUS patients treated with eculizumab, as a condition for approval. In September 2013, regulatory mandated post-marketing surveillance (PMS) was started to assess the long-term safety and effectiveness of eculizumab for all patients treated in Japan and will be completed by July 2018.

The diagnostic criteria for aHUS were defined in a Japanese clinical guide by the Japan Pediatric Society and Japanese Society of Nephrology, published in 2013 [8, 9]. In these guides, aHUS was broadly defined as any TMA excluding Shiga toxin–producing Escherichia coli (STEC)-HUS and thrombotic thrombocytopenic purpura (TTP) [8, 9]. The definition of aHUS has changed over time in Japan; therefore, the revised guide 2015 (published in 2016) limits the use of the term “aHUS” to complement-mediated HUS only, thereby excluding any TMA associated with transplantation, infection, drugs, autoimmune diseases, malignancies, or metabolic disorders (which is defined as “secondary TMA”) [2]. Nucleotide sequencing and analysis of complement genes were recommended; however, the identification of a pathogenic mutation is not always required for a diagnosis of aHUS [2]. Throughout this report, we use “aHUS” to mean complement-mediated HUS, according to the definition in the 2015 Japanese clinical guide. However, both aHUS and secondary TMA are included in the present analysis, because the broader (i.e., 2013) definition of aHUS was used for diagnosis in the patient population included.

The primary objective of this PMS is to collect data on the safety and effectiveness of long-term eculizumab treatment for all patients diagnosed with aHUS or secondary TMA who received at least one dose of eculizumab in Japan. Here, we report the real-world data in an interim analysis.

Methods

Study design and patients

The requirements of ethical approval by an institutional review board and informed consent from individual patients were waived for this regulatory mandated observational study. Patients younger than 18 years were enrolled if they had received an aHUS diagnosis from patient’s physician and had used eculizumab according to Japanese clinical guides [2, 8, 9] during the period from September 2013 to March 2017. The inclusion criteria were presence of MAHA, thrombocytopenia, and AKI; patients with STEC-HUS or TTP were excluded [8, 9]. MAHA was defined as a hemoglobin level of < 10 g/dL and thrombocytopenia as a platelet count (PLT) of < 15 × 10^9/μL. AKI in children was defined as a serum creatinine level at least 1.5 times the upper limit of the age- and sex-specific pediatric reference range [10]. The approved eculizumab dosing is based on the patient’s weight (Supplementary Table 1) [7].

Assessments of effectiveness and safety

The clinical endpoints of effectiveness, TMA event–free status, complete TMA response, hematologic outcomes, and renal outcomes, and the definitions of adverse events (AEs) and adverse reactions (ARs) of eculizumab were described in Supplementary Table 2.

Statistical analysis

Descriptive analysis of patient characteristics at the start of eculizumab treatment (baseline) was performed using median, mean, standard deviation (SD), and range (for continuous variables) and frequency and proportions (for categorical variables). Safety was summarized as the numbers of patients and incidence rates (in person-years) for each event in the safety analysis sets for aHUS and secondary TMA, respectively.

In the effectiveness analysis, clinical endpoints of effectiveness during treatment were indicated by the numbers and proportions of patients with aHUS who achieved the endpoint of interest. Absolute values and changes from baseline in PLT, lactate dehydrogenase (LDH), and eGFR were summarized using descriptive statics. Missing data were not imputed, except for body weight at the time of eculizumab administration, which was imputed using the most recent data before administration. Statistical analyses were performed with SAS version 9.1.3 (SAS Institute, Cary, NC). Two-sided P values (significance level 0.05) were used in all analyses.

Results

Pediatric patients enrolled in PMS

Forty-eight pediatric patients (31 with aHUS and 17 with secondary TMA) were enrolled. The meningococcal vaccine was administered to 54.2% of patients (26/48), 16 (61.5%, 16/26) received the vaccine after initiation of eculizumab treatment. Four patients (15.4%, 4/26) received...
prophylactic antibiotic therapy. Four patients were excluded from the effectiveness analysis, because they started eculizumab before drug approval and some data were thus not collected at baseline. Therefore, 44 pediatric patients—27 with aHUS and 17 with secondary TMA—were included in the effectiveness analysis.

Characteristics of patients with aHUS (complement-mediated HUS)

The characteristics of the 27 aHUS patients are summarized in Table 1. Median age (range) at the start of eculizumab treatment was 4 (0–16) years, and 11 (40.7%) patients were younger than 1 year. Median weight (range) was 14.9 (4.3–52.0) kg. DNA sequences of complement genes were examined in 21 patients; of these patients, genetic variants or autoantibodies were identified in 14 patients (66.7%), and 2 or more mutations/polymorphisms were found in 6 patients. Identified variants with an allele frequency of <0.005 in either ExAC or HGVD databases were found in 6 patients. Identified variants with an allele frequency of <0.005 in either ExAC or HGVD databases were found in 6 patients. Anti-CFH antibodies were detected in 3 patients, all of whom had CFHR1/3 deletions.

The median interval (range) from first TMA manifestation and aHUS diagnosis to the first dose of eculizumab was 14.0 (2–1692) days and 2.0 (1–1316) days, respectively (Table 1). Twenty-five of 27 patients (92.6%) started eculizumab treatment from the first TMA episode. Nineteen patients (70.4%) had received plasma therapy in the past year before eculizumab treatment. Thirteen patients (48.1%) were receiving dialysis at diagnosis.

The median (range) total duration of eculizumab treatment in aHUS patients at the data cutoff was 51.0 (0–125) weeks. Total duration of eculizumab treatment was <1 week for 2 patients, ≥1–<4 weeks for 2 patients, ≥4–<26 weeks for 3 patients, and ≥26 weeks for 20 patients. The dosing interval was altered for 18 of 27 patients (66.7%), and the dose was reduced for 2 patients (11.1%). At the date of data cutoff, 9 of 27 patients had discontinued eculizumab. Discontinuation of eculizumab was based on the doctor’s decision in 6 patients (improvement in 5 patients, isolation of STEC in 1 patient), death in 3 patients (described below), a family request in 1 patient and an AR in 1 patient (Supplementary Table 4). Three patients who discontinued eculizumab harbored abnormalities in complement genes; a patient who subsequently received a diagnosis of STEC-HUS had variants in MCP and CFB genes, another patient had anti-CFH antibodies and CFHR1/3 deletion, and the third patient harbored variants in CFH and MCP (Table 1). No variants were identified in 2 patients. Genetic tests were not performed for the remaining 4 patients.

Effectiveness of eculizumab in aHUS

Clinical endpoints of effectiveness during eculizumab treatment for pediatric patients are shown in Table 2. TMA event-free status was achieved in 23/27 patients (85.2, 95% confidence interval [CI] 66.3–95.8%). Complete TMA response and hematologic normalization, which were defined as maintenance of hematologic and renal outcomes for 4 weeks, were achieved in 8/22 patients (36.4, 95% CI 17.2–59.3%) and 9/22 patients (40.9, 95% CI 20.7–63.6%), respectively. The overall survival of aHUS patients was 88.4% (n=24), as shown in Supplementary Fig. 1.

PLT normalization was achieved in 18/23 patients (78.3, 95% CI 56.3–92.5%) (Table 2). Mean (SD) PLT was 8.89 (9.24) x 10^4/µL at baseline and 27.9 (14.0) x 10^4/µL at 10 days (Fig. 1). Mean increase of PLT from baseline to 10 days was 18.6 (15.7) x 10^4/µL (P<0.001). LDH normalization was achieved in 12/25 patients (48.0, 95% CI 27.8–68.7%). Mean (SD) LDH was 1315 (1045) IU/L at baseline and 349 (202) IU/L at 31 days (Fig. 1). Mean change in LDH from baseline to 31 days was a reduction of 1201 (1185) IU/L (P=0.001), although LDH levels in 92.6% (25/27) of patients had decreased by <404 IU/L at the end of observation (Supplementary Fig. 2a, b). An eGFR improvement of ≥15 ml/min/1.73 m² was achieved in 9/12 patients older than 2 years (75.0, 95% CI 42.8–94.5%). Mean (SD) eGFR was 40.4 (40.3) ml/min/1.73 m² at baseline and 102.5 (48.4) ml/min/1.73 m² at 31 days (Fig. 1). Mean increase in eGFR of individual patients from baseline to 31 days was 79.7 (43.3) ml/min/1.73 m² (P=0.003). Eight of 13 patients (61.5%) receiving dialysis at baseline were able to discontinue dialysis. Of the remaining 5 patients, 2 (1 younger than 2 years) continued dialysis and 3 died.

Safety analysis of aHUS patients

For the 31 pediatric aHUS patients in the safety analysis set, total exposure time was 33.0 patient-years. Twenty-four ARs (0.73 per patient-year) were reported in 8 patients (Table 3). ARs reported in 2 or more patients were hypertension and medical equipment–related infection (2 patients each, 0.06 per patient-year for each event); the other 20 ARs occurred in 1 patient each (0.03 per patient-year for all). No meningococcal infection was reported during eculizumab treatment or the observation period (Table 3).

Ten serious ARs were reported in four patients (0.30 per patient-year). The infection-related serious ARs were medical equipment–related infection (2 patients) and peritonitis and sepsis (1 patient each). One patient twice developed an infusion-site reaction (rash and/or wheeze), but both reactions resolved within 1 day.

The 3 aHUS patients who died were infants younger than 1 year (Supplementary Fig. 1 and Supplementary Table 4).
Table 1  Baseline demographics and disease characteristics of patients with aHUS (n = 27)

| Descriptive Category | Value |
|----------------------|-------|
| Median age at 1st eculizumab administration, years (range), n = 27 | 4.0 (0–16) |
| 1 month–<23 months, n (%) | 11 (40.7) |
| ≥23 months–<5 years, n (%) | 4 (14.8) |
| ≥5–<12 years, n (%) | 9 (33.3) |
| ≥12–<18 years, n (%) | 3 (11.1) |
| Median weight, kg (range), n = 27 | 14.90 (4.3–52.0) |
| Female sex, n (%) | 10 (37.0) |
| Patient reported family history of aHUS, n (%) | 3 (11) |
| Identified complement gene mutation, autoantibody or polymorphism, n (%)/examined | 14 (66.7)/21 |
| One mutation/polymorphism | 8 (57.1) |
| Two or more mutations/polymorphisms | 6 (42.9) |
| C3, n (%) | 3 (21.4) |
| CFB, n (%) | 2 (14.3) |
| CFH, n (%) | 4 (28.6) |
| CFHR1/3 deletion, n (%) | 4 (28.6) |
| anti-CFH antibody, n (%) | 3 (21.4) |
| CFI, n (%) | 0 (0.0) |
| MCP, n (%) | 5 (35.7) |
| DGKE, n (%) | 1 (7.1) |
| Other genes | 1 (7.1) |
| Median period from 1st TMA symptom to the first administration of eculizumab, (days) median (range), n = 27 | 14.0 (2–1692) |
| Median period from the day of diagnosis to the first administration of eculizumab (days), median (range), n = 27 | 2.0 (1–1316) |
| Plasma therapy (past 1 year), n (%) | 19 (70.4) |
| Median days of plasma therapy from the closest TMA to diagnosis to the first administration of eculizumab (days), median (range), n = 27 | 3.0 (0–53) |
| Dialysis at diagnosis (past 1 year), n (%) | 13 (48.1) |
| Previous renal transplant, n (%) | 0 (0.0) |
| Mean platelet count, × 10^9/µL, (SD), n = 27 | 8.89 (9.24) |
| Platelet count < 15 × 10^9/µL, n (%) | 23 (85.2) |
| Mean LDH level, U/l (SD), n = 27 | 1315.4 (1045.5) |
| LDH greater than ULN, n (%) | 25 (92.6) |
| Mean hemoglobin concentration, g/dl (SD), n = 27 | 8.63 (2.62) |
| Hemoglobin concentration < 10 g/dl, n = 27 | 24 (88.9) |
| Schistocytes positive, n (%)/examined | 6 (100) |
| Mean serum creatinine level, mg/dl (SD), n = 27 | 1.73 (1.63) |
| Mean eGFR, ml/min/1.73 m^2 (SD), n = 15 | 40.44 (40.32) |
| eGFR (ml/min/1.73 m^2), n | 15 |
| < 15, n (%) | 4 (26.7) |
| 15–29, n (%) | 6 (40.0) |
| 30–44, n (%) | 1 (6.7) |
| 45–59, n (%) | 1 (6.7) |
| 60–89, n (%) | 0 (0.0) |
| ≥ 90, n (%) | 3 (20.0) |
| Median duration of eculizumab treatment, weeks (range), n = 27 | 51.0 (0–125) |
| < 1 week, n (%) | 2 (7.4) |
| ≥ 1 week, < 4 weeks, n (%) | 2 (7.4) |
| ≥ 4 weeks, < 26 weeks, n (%) | 3 (11.1) |
| ≥ 26 weeks, n (%) | 20 (74.1) |

C3 Complement component 3, CFB complement factor B, CFH complement factor H, CFHR CFH-related protein, CFI thrombomodulin, MCP membrane cofactor protein, DGKE diacylglycerol kinase ε, CFHR1/3 denotes the locus from the CFHR3 to the CFHR1 genes, TMA thrombotic microangiopathy, LDH lactate dehydrogenase, ULN upper limit of normal, eGFR estimated glomerular filtration rate

The combinations of identified genetic variants were [C3- p.Ile1157Thr and MCP- p.Pro195Ser], [CFB- p.Leu9His and MCP- p.Ala311Val], [CFH- p.Hele17Leu- p.Arg1215Gln and CFHR5- p.Pro453Ser], [C3- p.Ser79Pro and CFH- p.His402Tyr- p.Glu936Asp], [CFH- p.His402Tyr- p.Glu936Asp and MCP- p.Thr163Ile], and [DGKE-c.71delT and -c.1213-2A > G]. CFH- p.His402Tyr and p.Glu936Asp are common variants in Japanese

CFHR5 variant p.Pro453Ser
The details of their clinical courses are described in the “Brief Case Report” in Supplementary Materials. In one patient, the AR that possibly resulted in death was pulmonary hemorrhage. The second patient died of acute heart failure and the third died of acute liver failure and exacerbation of renal dysfunction. None of these deaths was judged to be related to eculizumab.

**Patient characteristics and outcomes of TMA caused by underlying disease or complement-amplifying condition (secondary TMA)**

This interim analysis of the PMS included 17 patients with secondary TMA, which is referred to as secondary aHUS in other reports [12, 13]. Median age (range) at baseline was 2 (0–17) years, and 5 (29.4%) patients were younger than 2 years. Abnormalities of complement genes were identified in 3 of 5 patients tested. One had CFHR3-1 heterozygous deletion, another had CFHR2 heterozygous deletion with anti-CFH antibodies, and the third had homozygous deletion of the CFHR1 first intron. Table 4 summarizes the underlying diseases and complement-amplifying conditions (CACs) in those 17 patients. Two patients had infection (pneumococcal infection and Bordetella pertussis; n = 1 each), 1 had rheumatic disease (systemic lupus erythematosus), and 1 patient had a condition related to drug use. The underlying diseases were unknown in three patients. Ten patients (58.8%) had undergone hematopoietic stem cell transplantation (HSCT).

The median (range) total duration of eculizumab treatment was 3.0 (0–101) weeks. Three patients were treated with eculizumab for < 1 week, 6 patients for ≥ 1–< 4 weeks, 7 patients for ≥4–< 26 weeks, and 1 patient for ≥ 26 weeks. At the data cutoff, 16–17 patients had discontinued eculizumab therapy. The reason for discontinuation was the doctor’s decision in 9 patients (improvement in 7 patients, STEC-HUS diagnosis in 1 patient, and no description for the last patient). Three patients discontinued because of an insufficient response, 4 patients because of AEs, and 7 patients due to death (Supplementary Table 5). Among the 10 patients with HSCT-associated TMA (HSCT-TMA), 4 survived (3 of which experienced remission or improvement of TMA). Two patients (malignancy and STEC-HUS; n = 1 each) showed remission or improvement of TMA.

### Safety analysis in secondary TMA

For the 17 secondary TMA patients, total exposure time was 3.29 patient-years, and 10 ARs (3.04 per patient-year) were reported in 5 patients (Table 5). Each AR occurred once in a patient (0.30 per patient-year for all). Most ARs (9 of 10 events) were considered serious (2.74 per patient-year), and serious ARs were reported in five patients. The infection-related serious ARs were pneumonia, bacteremia, urinary tract infection, and herpes zoster. No meningococcal infection was reported during eculizumab treatment.

Eight patients with secondary TMA died, and 5 of these 8 patients (62.5%) had a malignancy. Six (75%) had HSCT-TMA, and half (3/6) of those with HSCT-TMA died after 1 or 2 doses of eculizumab. AEs that led to discontinuation of eculizumab therapy were progression of neuroblastoma, multi-organ failure, adenovirus infection, cerebral hemorrhage, and progression of EBV-associated lymphoproliferative disease. Seven deaths were judged to be unrelated to eculizumab. An AR related to death (leukopenia) was noted in 1 patient, as described in the “Brief Case Report” in the Supplementary Information.

### Discussion

Few retrospective and prospective clinical studies have evaluated the safety and efficacy of eculizumab in Japanese patients with aHUS [5, 6, 14–17]. The outcomes in this aHUS cohort

---

**Table 2 Clinical endpoints of effectiveness for patients with aHUS**

| Category                        | n (%) | 95% CI   |
|---------------------------------|-------|----------|
| **Hematologic outcome**         |       |          |
| Hematologic normalization, n    | 22    | 9 (40.9) |
| 95% CI                         |       | 20.7–63.6|
| Platelet count normalization, n | 23    | 18 (78.3)|
| 95% CI                         |       | 56.3–92.5|
| LDH normalization, n            | 25    | 12 (48.0)|
| 95% CI                         |       | 27.8–68.7|
| Hemoglobin improvement ≥ 2 g/dl, n | 27 | 17 (63.0) |
| 95% CI                         |       | 42.4–80.6|
| **Renal outcome**               |       |          |
| Serum creatinine level decrease by ≥ 25%, n | 27 | 18 (66.7) |
| 95% CI                         |       | 46.0–83.5|
| eGFR improvement by ≥ 15 ml/min/1.73 m², n | 12 | 9 (75.0)  |
| 95% CI                         |       | 42.8–94.5|

CI confidence interval, eGFR estimated glomerular filtration rate, LDH lactate dehydrogenase, TMA thrombotic microangiopathy

eGFR was calculated for pediatric patients aged 2 years through 18 years
PLT, LDH, and eGFR levels during eculizumab treatment of patients with aHUS. The eGFR for pediatric patients aged 2 years through 18 years was calculated using the following formulas, with "X" as body height (m):

\[
eGFR = 110.2 \times \left( -1.259 \times X + 7.815 \times 4 - 18.57 \times 3 + 21.39 \times 2 - 11.71X + 2.628 \right) / \text{serum creatinine} + 2.93 \text{ for boys and } 110.2 \times \left( -4.536 \times X + 27.16 \times 4 - 63.47 \times 3 + 72.43 \times 2 - 40.06X + 8.778 \right) / \text{serum creatinine} + 2.93 \text{ for girls} \] [11]. Although eGFR is generally used to evaluate chronic kidney disease, it was used to assess acute kidney dysfunction in this study. Changes from baseline were compared using the paired \( t \) test.
are consistent with those reported in previous clinical study [17] and showed improved TMA event-free status in Japanese pediatric patients treated with eculizumab. In a pivotal study of pediatric patients, the endpoints of TMA event-free status and PLT normalization were achieved in 95% of patients [17]. In the present analysis, 78 and 85% of patients, respectively, achieved these clinically relevant endpoints.

In a previous pediatric trial, the endpoint of complete TMA response was achieved in 64% of pediatric patients [17]. Despite successful achievement of TMA event-free status, complete TMA response was achieved in 36% of the present patients. Complete TMA response indicates improvement in the entire triad of PLT, LDH, and creatinine. Creatinine level decreased in 67% of patients, but LDH normalization was seen in fewer than half of patients. Both group and individual patient data showed that although LDH level clearly decreased within a few weeks, it did not reach the age-matched upper limit of normal in some patients, perhaps because of technical problems such as difference in institutional standards and hemolysis at blood sampling for a small child.

Existing evidence indicates that eculizumab is well-tolerated and that ARs are uncommon [5]. In this report, three infants with aHUS died. However, none of these deaths were related to eculizumab. A previous study suggests that 3% of Japanese population are nonresponders of eculizumab because of a specific C5 polymorphism leading to structural change of the C5 binding site of eculizumab [18]. Unfortunately, this polymorphism was not investigated in the present study.

Despite eculizumab treatment, patients with secondary TMA had poor outcomes. Eight of 17 patients died during the observation period. Most of these patients had underlying HSCT-TMA or malignancies: 4 of 10 patients with HSCT-TMA (40%) survived and 3 showed evidence of TMA improvement. A previous prospective observational study of HSCT-TMA showed that overall survival was significantly longer for pediatric patients treated with eculizumab than for those who did not receive eculizumab (62 vs. 9%, respectively, at 1 year after TMA diagnosis) [19, 20]. However, in that study eculizumab dose was increased significantly, which was not the case in this PMS study. Additional evidence will be required to determine whether adjustment of the timing and regimen for eculizumab administration improves outcomes for patients with HSCT-TMA [19, 20].

The Japanese Society of Nephrology has issued precautions for use of eculizumab in patients with secondary TMA [21], which is classified according to underlying conditions.

### Table 3 Treatment-emergent adverse reaction in patients with aHUS (n = 31)

| Adverse reaction                        | Number of cases (patient-years) | Number of cases (pers.-year) |
|----------------------------------------|---------------------------------|-----------------------------|
| Total exposure time (patient-years)     | 33.02                           | 10 (0.30)                   |
| Total number of manifestations         | 24 (0.73)                       | 10 (0.30)                   |
| Medical equipment-related infection    | 2 (0.06)                        | 2 (0.06)                    |
| Hypertension                           | 2 (0.06)                        | 1 (0.03)                    |
| Tympanitis                             | 1 (0.03)                        | 0 (0.00)                    |
| Acute otitis media                     | 1 (0.03)                        | 0 (0.00)                    |
| Peritonitis                            | 1 (0.03)                        | 1 (0.03)                    |
| Anal abscess                           | 1 (0.03)                        | 0 (0.00)                    |
| Sepsis                                 | 1 (0.03)                        | 1 (0.03)                    |
| Upper respiratory tract infection      | 1 (0.03)                        | 0 (0.00)                    |
| RS virus infection                     | 1 (0.03)                        | 0 (0.00)                    |
| Loss of appetite                       | 1 (0.03)                        | 0 (0.00)                    |
| Head discomfort                        | 1 (0.03)                        | 0 (0.00)                    |
| Seizures                               | 1 (0.03)                        | 1 (0.03)                    |
| Thrombosis                             | 1 (0.03)                        | 0 (0.00)                    |
| Pulmonary hemorrhage                   | 1 (0.03)                        | 1 (0.03)                    |
| Laryngeal stenosis                     | 1 (0.03)                        | 1 (0.03)                    |
| Vomiting                               | 1 (0.03)                        | 0 (0.00)                    |
| Hives                                  | 1 (0.03)                        | 0 (0.00)                    |
| Erythema                               | 1 (0.03)                        | 0 (0.00)                    |
| Rash                                   | 1 (0.03)                        | 0 (0.00)                    |
| Injection site reaction                | 1 (0.03)                        | 1 (0.03)                    |
| Fever                                  | 1 (0.03)                        | 0 (0.00)                    |
| Malaise                                | 1 (0.03)                        | 0 (0.00)                    |
or CACs [10, 22]. Findings from a retrospective study suggest that the benefits of eculizumab vary in relation to the underlying condition of secondary aHUS [22]. The present study could not address the effectiveness of eculizumab for each subgroup because of the small number of patients in each category, although five patients experienced remission or improvement of TMA. Thus, the benefit of eculizumab in secondary TMA should be carefully evaluated in future studies.

Mechanism of action of eculizumab may increase the risk of infection by encapsulated bacterial organisms, particularly Neisseria meningitidis from 1000-fold to 2000-fold compared to normal population [5, 23]. Although antimeningococcal vaccination is mandatory before the first dose of eculizumab except in the case of urgent treatment, meningococcal infection could occur even in patients who have received the vaccination [23]. In this study, none of

| Underlying diseases and complement-amplifying conditions in patients with secondary TMA (n = 17) |
|-------------------------------------------------------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Underlying disease/complement-amplifying conditions | No. of patients | Outcome | Improvement of symptoms/TMA | Remission | Insufficient response | Death | Other/unknown |
|-------------------------------------------------------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| HSCT |  | | | | | | |
| HSCT | 6 | – | 1*a | 1 | 4 (2)* | – |
| Complement dysregulation | 2 | – | 1*a | – | 1*c | – |
| Drug | 1 | – | – | – | 1 | – |
| Other | 1 | 1*a | – | – | – | – |
| Infection | 2 | – | – | 1 | – | 1*d |
| Drug | 1 | – | – | – | 1 | – |
| Rheumatic disease | 1 | – | – | – | – | 1 | |
| Unknown | 3 | 1*a | 1*b | – | – | 1 | – |

Hematopoietic stem cell transplantation (HSCT) includes bone marrow (n = 5), cord blood (n = 3) and autologous peripheral blood stem cells transplant (n = 2). Four of 10 patients with HSCT were treated with calcineurin inhibitors (tacrolimus) at least 1 year before eculizumab treatment. Parentheses denote 2 out of 4 patients had a malignant tumor as a complication
*aMalignancy
*bHeterozygous deletion of CFHR3-1
*cHeterozygous deletion of CFHR2 and anti-CFH antibody positive
*dEngraftment syndrome
*eEculizumab treatment was continued
*fSystemic lupus erythematosus
#gHomozygous deletion of the CFHR1 1st intron
*hDiagnosed as STEC-HUS afterward

| Treatment-emergent adverse reaction in patients with secondary TMA (n = 17) |
|-------------------------------------------------------------------------------|
| Adverse reaction | Serious adverse reaction |
| Number of cases (/person-year) | Number of cases (/person-year) |
|---------------------|---------------------|
| Total exposure time (patient-years) | 3.29 |
| Total number of manifestations | 10 (3.04) | 9 (2.74) |
| Pneumonia | 1 (0.30) | 1 (0.30) |
| Bacteremia | 1 (0.30) | 1 (0.30) |
| Urinary tract infection | 1 (0.30) | 1 (0.30) |
| Herpes zoster | 1 (0.30) | 1 (0.30) |
| Leukopenia | 1 (0.30) | 1 (0.30) |
| Hypertension | 1 (0.30) | 1 (0.30) |
| Pulmonary edema | 1 (0.30) | 1 (0.30) |
| Hives | 1 (0.30) | 0 (0.00) |
| Renal dysfunction | 1 (0.30) | 1 (0.30) |
| Fever | 1 (0.30) | 1 (0.30) |
the 13 infection-related ARs in aHUS and secondary TMA was related to *N. meningitides*. Importantly, no predominant pathogen was identified. However, one patient with neisserial infection, who fully recovered with appropriate antibiotic treatment, was reported after the data cutoff. In addition, in this study despite the mandatory requirement for vaccination, the percentage of meningococcal vaccination was relatively low (54.2%). An increased vigilance and education of the risk of meningococcal infection as a high-mortality disease and the requirement for vaccination will need to be put in place for patients treated with eculizumab in Japan.

This interim analysis had some limitations, including missing data and inadequate or incomplete follow-up, which resulted in variable patient numbers for assessments. Moreover, interpretation of disease characteristics and ARs by treating physicians may be inconsistent. As this was conducted in a clinical practice setting, there was no control group and greater variability in patient background, medical practice and treatment, (notably treatment duration was short and dosing was not as per approved regimen in a large proportion of patients) and follow-up schedule. Therefore, the results should be carefully interpreted.

In conclusion, this interim analysis confirmed that eculizumab is well-tolerated and effective for Japanese pediatric patients with aHUS in a real-world setting.

Acknowledgements PMS is mandatory and was conducted by Alexion Pharma GK, Tokyo, Japan, the sponsor and funder of this interim analysis. The authors thank all participating physicians and registered patients who participated in this study and their families. We also thank Jimmy Wang for a review of the statistical analysis plan and Asa Lomele, Christoph Gasteyger, and Michio Suzukawa, of Alexion Pharmaceuticals, for reviewing the manuscript. Cimic Ltd (Tokyo) performed all statistical analyses funded by Alexion Geneva Pharm. Statcom Co., Ltd. (Tokyo) provided medical writing support funded by Alexion Pharm. GK.

Compliance with ethical standards

Conflict of interest Employment: Takahisa Matsuda and Akihiko Shimono (Alexion Pharm. GK), Advisory role: Yoshitaka Miyakawa (Ablynx, Chugai Pharmaceutical Co., Ltd., FUJIFILM Pharma Co., Ltd, Novartis Pharmaceuticals and Zenyaku Kogyo Co., Ltd.), Stock ownership: Yoshitaka Miyakawa (Preventive Medicine), Patent royalties: Yoshihiro Fujimaru (Alfresa Pharma Corporation), Honoraria: Yoshihiko Hidaka, Norimitsu Inoue, Shuichi Ito, Shinya Kaname, Hideki Kato and Masanori Nangaku (Alexion Pharm. GK), Masanori Matsumoto (Alexion Pharm. GK and Asahi Kasei Pharm. Corporation), Hirokazu Okada (Alexion Pharm. GK and Kyowa Hakko Kirin Co. Ltd.), Yoshitaka Miyakawa (Alexion Pharm. GK, Bayer Yakuhin, Ltd., Baxalta Japan Limited, Biovertat, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Kyowa Hakko Kirin Co. Ltd., Novartis Pharmaceuticals, Teijin Pharma Limited and Zenyaku Kogyo Co., Ltd.), Shoichi Maruyama (Alexion Pharm. GK, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Kyowa Hakko Kirin Co. Ltd., Mochida Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd.), Research funding: Shoichi Maruyama (Sanwa Kagaku Kenkyusho Co., Ltd.) and Masanori Matsumoto (Bayer Yakuhin, Ltd., Baxalta Japan Limited and Chugai Pharmaceutical Co., Ltd.). Subsidies: Masao H. (Alexion Pharm. GK), Shuichi Ito (Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd. and Pfizer Japan Inc.), Shoichi Maruyama (Alexion Pharm. GK, Asahi Kasei Pharm. Corporation, Astellas Pharma Inc., Baxter, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Kissei Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma, Mochida Pharmaceutical Co. Ltd., MSD K.K., Nippon Boehringer Ingelheim Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., ROHTO Pharmaceutical Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Teijin Pharma Limited and Torii Pharmaceutical Co., Ltd.) and Hirokazu Okada (Astellas Pharma Inc., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma, MSD K.K., Nippon Boehringer Ingelheim Co., Novartis Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited and Torii Pharmaceutical Co., Ltd.), Endowed departments by commercial entities: Masashi Mizuno (Baxter Japan).

Ethical approval This PMS is conducted in accordance with Good Post-marketing Study Practice for drugs (MHLW Ministerial Ordinance no. 171 of 2004). The requirements of ethical approval by an institutional review board and informed consent from individual patients for this survey were waived.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. laurence J, Haller H, Mannucci PM, Nangaku M, Praga M, Rodriguez de Cordoba S. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14(Suppl 1):1–15.
2. Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:536–43.
3. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554–62.
4. Noris M, Caprioli J, Bresin E, Moscioni A, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844–59.
5. Legendre CM, Lich T, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.
6. Lich C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, et al. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061–73.
Affiliations

Shuichi Ito¹ · Yoshihiko Hidaka² · Norimitsu Inoue³ · Shinya Kaname⁴ · Hideki Kato⁵ · Masanori Matsumoto⁶ · Yoshitaka Miyakawa⁷ · Masashi Mizuno⁸ · Hirokazu Okada⁹ · Akihiko Shimono¹⁰ · Takahisa Matsuda¹⁰ · Shoichi Maruyama⁸ · Yoshihiro Fujimura¹¹ · Masaomi Nangaku⁷ · Shoji Kagami¹²

¹ Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukaura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan
² Clinical Division of Pediatrics, Shinshu University Hospital, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan
³ Department of Tumor Immunology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka 541-8567, Japan
⁴ Department of Nephrology and Rheumatology, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
⁵ Division of Nephrology and Endocrinology, The University of Tokyo, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan
⁶ Department of Blood Transfusion Medicine, Nara Medical University, 840 Shijyo-cho, Kasihihara, Nara 634-8522, Japan
⁷ Department of General Internal Medicine, Thrombosis and Hemostasis Center, Saitama Medical University Hospital, 38 Moroyama, Iruma-gun, Saitama 350-0495, Japan
⁸ Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi 466-8550, Japan
⁹ Saitama Medical University, 38 Moroyama, Iruma-gun, Saitama 350-0495, Japan
¹⁰ Alexion Pharma GK, 1-18-14 Ebisu, Shibuya-ku, Tokyo 150-0013, Japan
¹¹ Japanese Red Cross Kinki Block Blood Center, 7-5-17, Saitoasagi, Ibaraki, Osaka 567-0085, Japan
¹² Department of Pediatrics, Institute of Health Biosciences, The University of Tokushima Graduate School, Kuramoto cho 3-chome, Tokushima 770-8503, Japan

7. Soliris package insert version 8. In: Soliris website. http://www.soliris.jp/common/pdf/Soliris_Tempu_Bunsho_08.pdf. Accessed 19 Dec 2017. Japanese.
8. Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol. 2014;18:4–9.
9. Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, et al. Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Pediatr Int. 2014;56:1–5.
10. Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, et al. Age, gender, and body length effects on reference serum creatinine levels determined by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol. 2011;15:694–9.
11. Uemura O, Nagai T, Ishikura K, Ito S, Hataya H, Gotoh Y, et al. Creatinine-based equations to estimate glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626–33.
12. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017; 91:539–51.
13. Cavero T, Rabasco C, López A, Román E, Ávila A, Sevillano S, et al. Eculizumab in secondary atypical haemolytic uraemic syndrome. Nephrol Dial Transplant. 2017;32:466–74.
14. Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteiger C, et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 2015; https://doi.org/10.1186/s12882-015-0195-1.
15. Ito N, Hataya H, Saida K, Amano Y, Hidaka Y, Motoyoshi Y, et al. Efficacy and safety of eculizumab in childhood atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20:265–72.